Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 7, 2008, Pages 2435-2441

  Lek Uthai, U ^a   Suwanarusk, R ^b,c   Ruengweerayut, R ^d   Skinner Adams, T S ^e   Nosten, F ^a,f,g   Gardiner, D L ^e   Boonma, P ^a   Piera, K A ^b   Andrews, K T ^e   MacHunter, B ^b   McCarthy, J S ^e   Anstey, N M ^b   Price, R N ^b,g   Russell, B ^b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^c AGENCY FOR SCIENCE   (Singapore)

^d Mae Sod Hospital   (Thailand)

^e International and Tropical Health and Nutrition   (Australia)

^f SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^g CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; CHLOROQUINE; MEFLOQUINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; IC 50; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL;

ANIMALS; ANTIMALARIALS; DRUG RESISTANCE, MULTIPLE; GENE DOSAGE; GENES, MDR; GENES, PROTOZOAN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; RITONAVIR; SAQUINAVIR;

EID: 46249098615     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00169-08     Document Type: Article

References (38)

1. Alker, A. P., P. Lim, R. Sem, N. K. Shah, P. Yi, D. M. Bouth, R. Tsuyuoka, J. D. Maguire, T. Fandeur, F. Ariey, C. Wongsrichanalai, and S. R. Meshnick. 2007. Pfmdr1 and in vivo resistance to artesunate- mefloquine in falciparum malaria on the Cambodian-Thai border. Am. J. Trop. Med. Hyg. 76:641-647.
2. Andrews, K. T., M. L. Gatton, T. S. Skinner-Adams, J. S. McCarthy, and D. L. Gardiner. 2007. HIV-malaria interactions: don't forget the drugs. Science 315:1791.
3. Baird, J. K. 2004. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother. 48:4075-4083.
4. Banerjee, R., J. Liu, W. Beatty, L. Pelosof, M. Klemba, and D. E. Goldberg. 2002. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl. Acad. Sci. USA 99:990-995.
5. Bonilla, J. A., T. D. Bonilla, C. A. Yowell, H. Fujioka, and J. B. Dame. 2007. Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function. Mol. Microbiol. 65:64-75.
6. Brockman, A., R. N. Price, M. van Vugt, D. G. Heppner, D. Walsh, P. Sookto, T. Wimonwattrawatee, S. Looareesuwan, N. J. White, and F. Nosten. 2000. Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans. R. Soc. Trop. Med. Hyg. 94:537-544.
7. Brouwer, K. C., L. B. Mirel, C. Yang, R. B. Lal, M. S. Kolezak, A. M. Van Eijk, J. Ayisi, J. A. Otieno, B. L. Nahlen, R. Steketee, Y. P. Shi, and A. A. Lal. 2007. Subclinical Plasmodium falciparum infection and HIV-1 viral load. Emerg. Infect. Dis. 13:351-353.
8. Coombs, G. H., D. E. Goldberg, M. Klemba, C. Berry, J. Kay, and J. C. Mottram. 2001. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. Trends Parasitol. 17:532-537.
9. Dame, J. B., C. A. Yowell, L. Omara-Opyene, J. M. Carlton, R. A. Cooper, and T. Li. 2003. Plasmepsin 4, the food vacuole aspartic proteinase found in all Plasmodium spp. infecting man. Mol. Biochem. Parasitol. 130:1-12.
10. Dupuis, M. L., M. Flego, A. Molinari, and M. Cianfriglia. 2003. Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. HIV Med. 4:338-345.
11. - T lymphoblastid CEM cell line. Chemotherapy 49:8-16.
12. Ersmark, K., B. Samuelsson, and A. Hallberg. 2006. Plasmepsins as potential targets for new antimalarial therapy. Med. Res. Rev. 26:626-666.
13. Gusasira, A. F., M. R. Kamya, J. Achan, T. Mebrahtu, and J. N. Kalyango. 2008. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin. Infect. Dis. 46:985-991.
14. Li, T., C. A. Yowell, B. B. Beyer, S. H. Hung, J. Westling, M. T. Lam, B. M. Dunn, and J. B. Dame. 2004. Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man. Mol. Biochem. Parasitol. 135:101-109.
15. Liu, J., I. Y. Gluzman, M. E. Drew, and D. E. Goldberg. 2005. The role of Plasmodium falciparum food vacuole plasmepsins. J. Biol. Chem. 280:1432-1437.
16. Mendis, K., B. J. Sina, P. Marchesini, and R. Carter. 2001. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64:97-106.
17. Okereke, C. S. 1999. Management of HIV-infected pregnant patients in malaria-endemic areas: therapeutic and safety considerations in concomitant use of antiretroviral and antimalarial agents. Clin. Ther. 21:1456-1496. 1427-1428.
18. Omara-Opyene, A. L., P. A. Moura, C. R. Sulsona, J. A. Bonilla, C. A. Yowell, H. Fujioka, D. A. Fidock, and J. B. Dame. 2004. Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy. J. Biol. Chem. 279:54088-54096.
19. Owen, A., O. Janneh, R. C. Hartkoorn, B. Chandler, P. G. Bray, P. Martin, S. A. Ward, C. A. Hart, S. H. Khoo, and D. J. Back. 2005. In vitro synergy and enhanced murine brain penetration of saquinavir coadministered with mefloquine. J. Pharmacol. Exp. Ther. 314:1202-1209.
20. Parikh, S., J. Gut, E. Istvan, D. E. Goldberg, D. V. Havlir, and P. J. Rosenthal. 2005. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob. Agents Chemother. 49:2983-2985.
21. Parikh, S., J. Liu, P. Sijwali, J. Gut, D. E. Goldberg, and P. J. Rosenthal. 2006. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrob. Agents Chemother. 50:2207-2209.
22. Price, R., C. Luxemburger, M. van Vugt, F. Nosten, A. Kham, J. Simpson, S. Looareesuwan, T. Chongsuphajaisiddhi, and N. J. White. 1998. Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 92:207-211.
23. Price, R. N., C., Cassar, A. Brockman, M. Duraisingh, M. van Vugt, N. J. White, F. Nosten, and S. Krishna. 1999. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 43:2943-2949.
24. Price, R. N., E. Tjitra, C. A. Guerra, S. Yeung, N. J. White, and N. M. Anstey. 2007. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 77:79-87.
25. Price, R. N., A. C. Uhlemann, A. Brockman, R. McGready, E. Ashley, L. Phaipun, R. Patel, K. Laing, S. Looareesuwan, N. J. White, F. Nosten, and S. Krishna. 2004. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364:438-447.
26. Pukrittayakamee, S., A. Chantra, J. A. Simpson, S. Vanijanonta, R. Clemens, S. Looareesuwan, and N. J. White. 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob. Agents Chemother. 44:1680-1685.
27. Redmond, A. M., T. Skinner-Adams, K. T. Andrews, D. L. Gardiner, J. Ray, M. Kelly, and J. S. McCarthy. 2007. Antimalarial activity of sera from subjects taking HIV protease inhibitors. AIDS 21:763-765.
28. Rojanawatsirivet, C., K. Congpuong, S. Vijaykadga, S. Thongphua, K. Thongsri, K. N. Bangchang, P. Wilairatana, and W. H. Wernsdorfer. 2004. Declining mefloquine sensitivity of Plasmodium falciparum along the Thai-Myanmar border. Southeast Asian J. Trop. Med. Public Health 35:560-565.
29. Russell, B., F. Chalfein, B. Prasetyorini, E. Kenangalem, K. Piera, R. Suwanarusk, A. Brockman, P. Prayoga, P. Sugiarto, Q. Cheng, E. Tjitra, N. M. Anstey, and R. N. Price. 2008. Determinants of in vitro drug susceptibility testing of Plasmodium vivax. Antimicrob. Agents Chemother. 52:1040-1045.
30. Russell, B. M., R. Udomsangpetch, K. H. Rieckmann, B. M. Kotecka, R. E. Coleman, and J. Sattabongkot. 2003. Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalariais in areas where P. vivax is endemic. Antimicrob. Agents Chemother. 47:170-173.
31. Skinner-Adams, T. S., K. T. Andrews, L. Melville, J. McCarthy, and D. L. Gardiner. 2007. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 51:759-762.
32. Skinner-Adams, T. S., J. S. McCarthy, D. L. Gardiner, and K. T. Andrews. 2 May 2008, posting date. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends Parasitol. doi:10.1016/j.pt.2008.03.008.
33. Skinner-Adams, T. S., J. S. McCarthy, D. L. Gardiner, P. M. Hilton, and K. T. Andrews. 2004. Antiretrovirals as antimalarial agents. J. Infect. Dis. 190:1998-2000.
34. Slutsker, L., and B. J. Marston. 2007. HIV and malaria: interactions and implications. Curr. Opin. Infect. Dis. 20:3-10.
35. Suwanarusk, R., B. Russell, M. Chavchich, F. Chalfein, E. Kenangalem, V. Kosaisavee, B. Prasetyorini, K. A. Piera, M. Barends, A. Brockman, U. Lek-Uthai, N. M. Anstey, E. Tjitra, F. Nosten, Q. Cheng, and R. N. Price. 2007. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. PLoS ONE 2:e1089.
36. Uhlemann, A. C., R. McGready, E. A. Ashley, A. Brockman, P. Singhasivanon, S. Krishna, N. J. White, F. Nosten, and R. N. Price. 2007. Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J. Infect. Dis. 195:134-141.
37. Verhoeff, F. H., B. J. Brabin, C. A. Hart, L. Chimsuku, P. Kazembe, and R. L. Broadhead. 1999. Increased prevalence of malaria in HIV-infected pregnant women and its implications for malaria control. Trop. Med. Int. Health 4:5-12.
38. Williams, G. C., A. Liu, G. Knipp, and P. J. Sinko. 2002. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob. Agents Chemother. 46:3456-3462.